Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
Janux Therapeutics Inc (JANX) Stock Price & Analysis
167 Followers
JANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.65 - $64.79
Previous Close$62.43
Volume1.05M
Average Volume (3M)1.02M
Market Cap
$3.02B
Enterprise Value$2.92B
Total Cash (Recent Filing)$344.03M
Total Debt (Recent Filing)$24.54M
Price to Earnings (P/E)-46.5
Beta1.95
Next Earnings
May 07, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding51,660,060
10 Day Avg. Volume841,873
30 Day Avg. Volume1,018,743
Standard Deviation0.84
R-Squared0.06
Alpha0.12
Financial Highlights & Ratios
Price to Book (P/B)8.73
Price to Sales (P/S)374.49
Price to Cash Flow (P/CF)-75.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue483.44
Enterprise Value/Gross Profit338.78
Enterprise Value/Ebitda-62.76
Forecast
1Y Price Target
$63.83Price Target Upside-1.47% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Janux Therapeutics Inc News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsJanux Therapeutics shows a promising lead in oncology with its innovative TRACTr platform that has demonstrated robust initial data, suggesting potential to revolutionize treatment in solid tumors.
Financial StabilityWith a robust cash position and recent successful financing, Janux Therapeutics is well positioned financially to achieve key milestones and advance its leading oncology treatments.
Market PotentialAnalyst recommends a buy rating with a significant price target for Janux Therapeutics, bolstered by strong clinical data and the potential for high efficacy of its lead pipeline assets.
Bears Say
Company OutlookWhile there's downside risk responses in the 2H may not meet expectations.
Financial PerformanceJANX reported a Q4 net loss of $11.8MM.
Operational RisksRisks include clinical, regulatory, commercial, partnership, financial, and intellectual property challenges that could impact the stock's performance.
---
Ownership Overview
72.02% Insiders
14.20% Mutual Funds
4.77% Other Institutional Investors
9.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $5.65 and its highest was $64.79 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Currently, no data Available
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is May 07, 2024 which is 2 days ago.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Mar 08, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.415 by $0.165.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Overvalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -$0.33.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 51,850,666 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.415. Following the earnings report the stock price went up 0.402%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Among the largest hedge funds holding Janux Therapeutics Inc’s share is RA Capital Management. It holds Janux Therapeutics Inc’s shares valued at 98M.
---
Janux Therapeutics Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.83 (-1.47% Downside)
$63.83 (-1.47% Downside)
Blogger Sentiment
Bullish
JANX Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 85.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 34.7%
Last 30 Days ▲ 34.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
320.12%
12-Months-Change
Fundamentals
Return on Equity
-17.53%
Trailing 12-Months
Asset Growth
4.50%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
---
JANX Stock 12 Month Forecast
Average Price Target
$63.83
▼(-1.47% Downside)
Technical Analysis
Best Analysts Covering JANX
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+143.31%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +143.31% per trade.
---